We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche Ocrevus Positive in Phase III Multiple Sclerosis Trials
Read MoreHide Full Article
Roche Holdings (RHHBY - Free Report) announced that new analyses from three phase III studies on its multiple sclerosis candidate, Ocrevus, will be presented at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), scheduled for Sep 14-17 in London, England.
The phase III development program for the candidate comprises three studies – OPERA I, OPERA II and ORATORIO.
Separate post-hoc analyses showed Ocrevus increased disease control in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
A higher proportion of RMS patients (75%) achieved No Evidence of Disease Activity (NEDA) when treated with Ocrevus, compared with the interferon beta-1a (Rebif) arm. Moreover, a higher proportion of PPMS patients (47%) achieved No Evidence of Progression (NEP) with Ocrevus compared with placebo.
We remind investors that the FDA has accepted Roche’s Biologics License Application (BLA) for Ocrevus for the treatment of RMS and PPMS, and granted the candidate Priority Review Designation with a targeted action date of Dec 28, 2016. The European Medicines Agency (EMA) has also accepted the company’s marketing applications for Ocrevus for RMS and PPMS.
Roche dominates the breast cancer space with strong demand for its HER2 franchise drugs Herceptin, Perjeta and Kadcyla. We are impressed by the company's efforts to grow its portfolio beyond oncology and foray into new avenues such as multiple sclerosis and asthma.
Furthermore, Roche currently has more than a dozen investigational candidates in its pipeline for diseases that include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, Parkinson’s disease and autism.
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Roche Ocrevus Positive in Phase III Multiple Sclerosis Trials
Roche Holdings (RHHBY - Free Report) announced that new analyses from three phase III studies on its multiple sclerosis candidate, Ocrevus, will be presented at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), scheduled for Sep 14-17 in London, England.
The phase III development program for the candidate comprises three studies – OPERA I, OPERA II and ORATORIO.
Separate post-hoc analyses showed Ocrevus increased disease control in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
A higher proportion of RMS patients (75%) achieved No Evidence of Disease Activity (NEDA) when treated with Ocrevus, compared with the interferon beta-1a (Rebif) arm. Moreover, a higher proportion of PPMS patients (47%) achieved No Evidence of Progression (NEP) with Ocrevus compared with placebo.
ROCHE HLDG LTD Price
ROCHE HLDG LTD Price | ROCHE HLDG LTD Quote
We remind investors that the FDA has accepted Roche’s Biologics License Application (BLA) for Ocrevus for the treatment of RMS and PPMS, and granted the candidate Priority Review Designation with a targeted action date of Dec 28, 2016. The European Medicines Agency (EMA) has also accepted the company’s marketing applications for Ocrevus for RMS and PPMS.
Roche dominates the breast cancer space with strong demand for its HER2 franchise drugs Herceptin, Perjeta and Kadcyla. We are impressed by the company's efforts to grow its portfolio beyond oncology and foray into new avenues such as multiple sclerosis and asthma.
Furthermore, Roche currently has more than a dozen investigational candidates in its pipeline for diseases that include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, Parkinson’s disease and autism.
Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Ligand Pharmaceuticals (LGND - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Pacira Pharmaceuticals (PCRX - Free Report) . All these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>